Articles tagged with Sars Cov 2
Researchers found substantial declines in outpatient clinic visits (7%) and hospitalizations (13%) compared to expected levels. Long-term disruptions persist, with 65% of regions experiencing non-rebound outpatient visits and 74% with reduced hospitalizations.
Researchers used high-frequency ultrasound waves to eliminate viruses such as SARS-CoV-2 and H1N1 by causing structural changes that led to inactivation. The technique uses acoustic resonance, which differs from cavitation, a process used for decontamination.
Researchers discovered that early-stage ectoderm cells are especially susceptible to SARS-CoV-2 infection, with heightened vulnerability driven by elevated TMPRSS2 activity and thinner glycocalyx. This raises concerns about potential developmental risks, particularly for infants born to mothers infected during early pregnancy.
Researchers found no evidence of persistent SARS-CoV-2 in placentas collected from women who recovered from COVID-19. However, structural and inflammatory changes were observed in some placentas, suggesting the immune response may outlast the virus.
Researchers have found that COVID vaccines can train immune cells to remember the SARS-CoV-2 virus and protect against severe infection for years afterward. However, the continued spread of disease has scientists taking a closer look at how the immune system builds up immune memory over time.
Researchers observed nonrandom patterns of spike D614 reversions in SARS-CoV-2 delta and omicron BA.2 variants, suggesting a non-spontaneous mechanism. These reversions occurred disproportionately after peak transmission periods and showed geographic clustering.
Among highly boosted patients with cancer, overall postacute sequelae risk was not elevated compared to noninfected patients; hospitalized COVID-19 patients remained at increased risk despite therapeutics. Vaccination and boosting remain important in mitigating long COVID among immunocompromised patients
Researchers redesigned a key component of lipid nanoparticles to steer particles toward lymph nodes, reducing off-target delivery. This advancement could make mRNA vaccines more efficient, potentially achieving strong immune protection at lower doses.
Researchers at the University of Pennsylvania developed lipid nanoparticles that modify immune metabolism to strengthen mRNA vaccines and reduce common side effects. The new lipid boosts the metabolism of immune cells, providing energy for the body's defenses while dialing down inflammatory signals.
A new UC San Diego study challenges the idea that pandemic viruses require rare adaptations in animals to infect humans. The research found that most zoonotic viruses, including COVID-19, do not show evidence of prior adaptation before emerging in humans.
A study from the University of East Anglia found that Covid lockdowns disrupted children's ability to self-regulate, leading to slower growth in executive functions. Reception-age children, who normally learn to socialize and navigate classroom routines, showed significant setbacks in cognitive flexibility and self-regulation skills.
A randomized, double-blind clinical trial found that a natural fungal supplement, FoTv, reduced short-term vaccine side effects and helped antibodies last longer in people who had not previously been exposed to COVID-19. The study suggests that FoTv may help strengthen vaccine protection without increasing side effects.
The study found that the intranasal vaccine booster Clec9A OMNI induced significantly stronger neutralising antibody responses and robust T-cell responses in the lungs and nasal tissues, offering robust protection against SARS-CoV-2 Omicron infection. This breakthrough may address current shortcomings of COVID-19 mRNA vaccines, includi...
A recent study published in Science Translational Medicine found that infant immune systems respond very differently to RSV and SARS-CoV-2, with important treatment implications. Infants infected with RSV often develop severe symptoms due to low levels of systemic inflammation and a poorly coordinated early immune response.
A study from Linköping University in Sweden found no association between COVID-19 vaccination and decreased childbirth rates. Researchers analyzed data on over 60,000 women and found no statistically significant difference between vaccinated and unvaccinated groups.
The study found that 2024-2025 COVID-19 vaccines offer protection against COVID-19 hospitalization and severe in-hospital outcomes. Monitoring vaccine effectiveness remains crucial to guide vaccine composition and recommendations.
A new hypothesis article proposes that HPV E6 and SARS-CoV-2 spike proteins could cooperate in suppressing host defenses including tumor suppressor mechanisms involving p53. Laboratory studies suggest that combined viral pressures on tumor-suppressor pathways may contribute to cancer progression.
A new study reveals that COVID-19 vaccination influences long-term immunity, with those vaccinated first showing stronger antibody responses to Omicron variants. The study found higher levels of IgG and IgA antibodies in vaccinated individuals, but a stronger T-cell response in those infected first.
This study found that vaccination before and during COVID-19 diagnosis in pregnancy significantly lowers the risk of severe maternal illness and premature birth. The results suggest that COVID-19 vaccination plays a crucial role in protecting pregnant individuals from serious health complications associated with the virus.
Research by Politecnico di Milano finds that even a small percentage of individuals who don't follow health measures can significantly increase the infection peak and strain healthcare facilities. The study emphasizes the need to monitor and adapt public health strategies to individual urban contexts, making interventions more effective.
Researchers have identified promising compounds that can combat resistant COVID-19 variants by targeting an enzyme similar to one used by Chagas disease. Compounds 5a and 5b, synthesized from older chemical libraries, demonstrated strong Mpro inhibition with low toxicity.
Researchers discovered a 'sticky' molecule, P-selectin, that can cause blood clots and organ failure during COVID-19. A new mRNA therapy that drives P-selectin expression provides broad protection against coronavirus infection.
Researchers at EMBL-EBI developed SPRTA, an interpretable and efficient way to score the reliability of each branch in a phylogenetic tree. This method enables fast and reliable understanding of virus strain evolution, informing better decisions during outbreaks.
Patients with advanced lung and skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer. The vaccine was associated with a near doubling of median survival, from 20.6 months to 37.3 months in lung cancer patients.
Researchers argue that AI can strengthen pandemic preparedness by detecting emerging diseases earlier. By combining data from humans, animals, and the environment, AI can reveal patterns and provide insights into potential pathogens.
A new pediatric study found that young people infected with COVID twice are twice as likely to develop long COVID, with increased risks for heart disease, damaged kidneys, cognitive issues, and more. The study analyzed data from over 407,000 patients across 40 pediatric hospitals.
A cohort study investigated olfactory dysfunction in US adults with and without prior SARS-CoV-2 infection. The study found a significant association between prior infection and persistent olfactory dysfunction. High variability was observed among individuals, highlighting the need for individualized assessment and treatment strategies.
Researchers discovered that COVID-19 can persist in gastrointestinal tissue for up to six weeks after a positive nasal swab test, leading to increased inflammation and damage. The study highlights the need for monitoring patients with high levels of SERPINA1, who may be at risk for poor outcomes.
Scientists at Scripps Research have pinpointed dozens of human proteins that SARS-CoV-2 needs to complete its full life cycle. Two promising drug targets, perlecan and BIRC2, show potential in blocking coronaviruses at multiple stages of infection.
A clinical trial led by Professor Robert Bals found that azelastine nasal spray significantly reduced the risk of SARS-CoV-2 infection by 66%. The treatment group showed fewer symptomatic infections and lower respiratory rates compared to the placebo group.
The COVID-19 virus replicates using cellular machinery responsible for testosterone production, altering lipid metabolism and potentially leading to lower testosterone levels. This study reveals the mechanism by which SARS-CoV-2 targets testicular cells, offering insights into male vulnerability to COVID-19.
Patients with Long COVID are using digital tools and online communities to track symptoms, identify patterns, and develop care plans. Despite medical dismissiveness, self-tracking data helps patients advocate for diagnostic tests and treatment.
A comprehensive epidemiological study found that people who had COVID-19 are at increased risk of developing certain inflammatory diseases of the airways, such as asthma and chronic sinusitis. Vaccination against SARS-CoV-2 virus appears to reduce this risk.
Adults with long COVID experience worse work impairment, missed work, and financial distress compared to those without long COVID. Vaccination is associated with improved work outcomes and reduced financial distress among individuals with long COVID.
This book delves into the scientific foundations of mucosal vaccine platforms, discussing immunological mechanisms, novel adjuvants, and real-world development challenges. It serves as a valuable resource for professionals and students in life sciences, immunology, and pharmacology.
A new study from UCLA finds that the definition of Long COVID varies widely across published studies, resulting in dramatically different estimated prevalence rates. The study highlights the need for a standardized definition to advance research and improve patient care.
A synthetic glycosystem mimics natural sugars on human cells, binding to virus's spike protein and preventing infection. The molecule was found to be effective at low doses and worked against multiple SARS-CoV-2 strains.
A multi-year clinical research study in US children documents the rebound of endemic respiratory viruses after the COVID-19 pandemic. The study shows that non-pharmaceutical interventions decreased circulation rates of common respiratory pathogens in children, enabling more accurate predictions for future outbreaks.
Scientists have identified a previously unknown virus in Pacific oysters linked to annual mass die-offs, highlighting the importance of disease prevention measures. The discovery also underscores the need for further research into the causes of mortality in oyster populations.
Researchers at Stanford Medicine have developed a virtual lab powered by AI, allowing them to tackle complex biological problems and devise innovative solutions. The virtual lab has been successfully tested in devising a new basis for a vaccine against recent COVID-19 variants using nanobodies.
Researchers at Chan Zuckerberg Biohub San Francisco and Stanford University have developed an AI-driven Virtual Lab that can tackle sophisticated scientific problems. The team of AI agents, each equipped with varied expertise, can formulate, refine, and carry out complex research strategies, producing results that can be validated in r...
A new UNLV-led study uses AI to detect emerging virus variants in wastewater samples, outperforming existing methods. The algorithm can identify unique signatures for different virus variants with as few as two to five samples, significantly earlier than current methods.
Researchers developed a new analysis method for CoVerage that predicts SARS-CoV-2 Variants of Concern (VOCs) with a lead time of almost three months. The tool analyzes genomic data to identify antigenic changes in the virus, enabling early detection and characterization of VOCs.
Researchers developed a lyophilized open-source RT-LAMP assay for pathogen detection, making diagnostics more accessible and affordable globally. The assay is heat stable, requires no cold chain, and can detect various pathogens with high sensitivity.
The BA.2.86 Omicron strain was found to have emerged with a high number of genetic mutations in its spike protein, but failed to become a dominant strain. Its sporadic global detection has raised questions about the possibility of laboratory involvement in its emergence.
A new analysis has found a higher risk of arterial and venous thrombosis after COVID-19 infection compared to vaccination. The study also identified an increased risk of thrombosis following the first dose of the AZD1222 vaccine, but not with subsequent doses.
A University of Minnesota research team has found that measuring SARS-CoV-2 in wastewater continues to accurately predict subsequent COVID-19 case counts in a community. The study demonstrates the continued importance of wastewater surveillance for public health planning and informing real-time decision-making frameworks.
A new study reveals that the SARS-CoV-2 nucleocapsid protein can spread between cells, triggering an immune response that mistakenly targets healthy cells. The researchers found that a commonly used anticoagulant, enoxaparin, can block this harmful interaction, potentially offering a new avenue for treatment.
Scientists have modified mRNA vaccines to include the cytokine IL-12, enhancing T cell responses and improving protection against diseases such as SARS-CoV-2, influenza, melanoma, and listeria infection. The study's findings suggest a promising approach to enhance immune stimulation against cancer and other pathogens.
Researchers at EPFL have created ultra-selective aptamers that target specific binding sites on viral spike proteins with unprecedented precision. These multivalent binders show stronger and more selective binding affinities than traditional monovalent binders, making them promising for biomedical diagnostics and therapeutics.
A new technology using microscopic beads marked with stable isotopes enables the simultaneous detection of dozens of different antibodies in hundreds of samples. This expands the capacity of serological analysis for biomedical research, vaccine development, and epidemiological studies.
An international team of researchers has identified a genetic link to long-term symptoms after COVID-19, with a gene variant increasing the risk by about 60%. The variant is located near the FOXP4 gene, which affects lung function and development. Impaired lung function plays a key role in developing long COVID.
A recent study by UFZ reveals that PFAS influence the cellular immune response to SARS-CoV-2, particularly in males. The researchers found that high PFAS exposure alters the immune response, potentially reducing its effectiveness and increasing the risk of poor disease progression.
The study found that mRNA-1083 induced higher immune responses than standard care influenza and COVID-19 vaccines, with an acceptable tolerability and safety profile. The vaccine met noninferiority criteria for all 4 influenza strains and SARS-CoV-2 across various age groups.
Researchers at Karolinska Institutet have identified biomarkers in the blood associated with long COVID symptoms, particularly severe respiratory disorders. The study found that these biomarkers are also linked to inflammatory signal pathways involved in cell death and lung damage.
The CoVaRR-Net network successfully bridged critical research and public health gaps exposed by the COVID-19 pandemic through interdisciplinary collaboration and innovative approaches like wastewater surveillance. Its achievements include 139 peer-reviewed publications, evidence-based public health decisions, and a global leader in ear...
Researchers at UCSF's AViDD Center have developed a highly bioavailable, covalent molecule that inhibits coronavirus MPro with potent in vivo efficacy. This discovery holds promise for preventing future coronavirus pandemics.
Researchers at UCSF's AViDD Center have developed powerful drug candidates that outperformed Paxlovid in preclinical testing against SARS-CoV-2 and MERS. The compounds could inhibit coronaviruses in general, providing a head start against future pandemics.